[HTML][HTML] The role of ubiquitination in tumorigenesis and targeted drug discovery

L Deng, T Meng, L Chen, W Wei, P Wang - Signal transduction and …, 2020 - nature.com
Ubiquitination, an important type of protein posttranslational modification (PTM), plays a
crucial role in controlling substrate degradation and subsequently mediates the “quantity” …

Chemistry and biology of multicomponent reactions

A Domling, W Wang, K Wang - Chemical reviews, 2012 - ACS Publications
Multicomponent reactions (MCRs) are one-pot reactions employing more than two starting
materials, for example, 3, 4,..., 7, where most of the atoms of the starting materials are …

Ferroptosis as a p53-mediated activity during tumour suppression

L Jiang, N Kon, T Li, SJ Wang, T Su, H Hibshoosh… - Nature, 2015 - nature.com
Although p53-mediated cell-cycle arrest, senescence and apoptosis serve as critical barriers
to cancer development, emerging evidence suggests that the metabolic activities of p53 are …

MDM2, MDMX and p53 in oncogenesis and cancer therapy

M Wade, YC Li, GM Wahl - Nature Reviews Cancer, 2013 - nature.com
The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many
human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour …

Mutant p53 in cancer: accumulation, gain-of-function, and therapy

X Yue, Y Zhao, Y Xu, M Zheng, Z Feng, W Hu - Journal of molecular biology, 2017 - Elsevier
Tumor suppressor p53 plays a central role in tumor suppression. p53 is the most frequently
mutated gene in human cancer, and over half of human cancers contain p53 mutations …

Drugging the p53 pathway: understanding the route to clinical efficacy

KH Khoo, CS Verma, DP Lane - Nature reviews Drug discovery, 2014 - nature.com
The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more
than half of all human tumours carrying mutations in this particular gene. Intense efforts to …

Stapled α− helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

YS Chang, B Graves, V Guerlavais… - Proceedings of the …, 2013 - National Acad Sciences
Stapled α− helical peptides have emerged as a promising new modality for a wide range of
therapeutic targets. Here, we report a potent and selective dual inhibitor of MDM2 and …

The first 30 years of p53: growing ever more complex

AJ Levine, M Oren - Nature reviews cancer, 2009 - nature.com
Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen,
the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 …

Awakening guardian angels: drugging the p53 pathway

CJ Brown, S Lain, CS Verma, AR Fersht… - Nature Reviews …, 2009 - nature.com
Currently, around 11 million people are living with a tumour that contains an inactivating
mutation of TP53 (the human gene that encodes p53) and another 11 million have tumours …

[HTML][HTML] P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer's disease

KM Farmer, G Ghag, N Puangmalai… - Acta neuropathologica …, 2020 - Springer
The transcription factor, p53, is critical for many important cellular functions involved in
genome integrity, including cell cycle control, DNA damage response, and apoptosis …